Literature DB >> 18461053

Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Jiehua Zhou1, Haitang Li, Shirley Li, John Zaia, John J Rossi.   

Abstract

The successful use of small interfering RNAs (siRNAs) for therapeutic purposes requires safe and efficient delivery to specific cells and tissues. In this study, we demonstrate cell type-specific delivery of anti-human immunodeficiency virus (anti-HIV) siRNAs through fusion to an anti-gp120 aptamer. The envelope glycoprotein is expressed on the surface of HIV-1-infected cells, allowing binding and internalization of the aptamer-siRNA chimeric molecules. We demonstrate that the anti-gp120 aptamer-siRNA chimera is specifically taken up by cells expressing HIV-1 gp120, and that the appended siRNA is processed by Dicer; this releases an anti-tat/rev siRNA which, in turn, inhibits HIV replication. We show for the first time a dual functioning aptamer-siRNA chimera in which both the aptamer and the siRNA portions have potent anti-HIV activities. We also show that gp120 expressed on the surface of HIV-infected cells can be used for aptamer-mediated delivery of anti-HIV siRNAs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461053      PMCID: PMC2727148          DOI: 10.1038/mt.2008.92

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

1.  Escort aptamers: a delivery service for diagnosis and therapy.

Authors:  B J Hicke; A W Stephens
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Peptide-based strategy for siRNA delivery into mammalian cells.

Authors:  Federica Simeoni; May C Morris; Frederic Heitz; Gilles Divita
Journal:  Methods Mol Biol       Date:  2005

3.  Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy.

Authors:  Dong-Ho Kim; Mark A Behlke; Scott D Rose; Mi-Sook Chang; Sangdun Choi; John J Rossi
Journal:  Nat Biotechnol       Date:  2004-12-26       Impact factor: 54.908

4.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA.

Authors:  Charles R Allerson; Namir Sioufi; Russell Jarres; Thazha P Prakash; Nishant Naik; Andres Berdeja; Lisa Wanders; Richard H Griffey; Eric E Swayze; Balkrishen Bhat
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

5.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Authors:  David V Morrissey; Jennifer A Lockridge; Lucinda Shaw; Karin Blanchard; Kristi Jensen; Wendy Breen; Kimberly Hartsough; Lynn Machemer; Susan Radka; Vasant Jadhav; Narendra Vaish; Shawn Zinnen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Lloyd B Jeffs; Adam Judge; Ian MacLachlan; Barry Polisky
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

6.  Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.

Authors:  Antu K Dey; Carla Griffiths; Susan M Lea; William James
Journal:  RNA       Date:  2005-06       Impact factor: 4.942

7.  Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.

Authors:  David V Morrissey; Karin Blanchard; Lucinda Shaw; Kristi Jensen; Jennifer A Lockridge; Brent Dickinson; James A McSwiggen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Barry A Polisky; Shawn Zinnen
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

8.  Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency.

Authors:  Tae Woo Kim; Jin-Hyup Lee; Liangmei He; David A K Boyd; J Marie Hardwick; Chien-Fu Hung; T-C Wu
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

9.  Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels.

Authors:  Zahra Hassani; Gregory F Lemkine; Patrick Erbacher; Karima Palmier; Gladys Alfama; Carine Giovannangeli; Jean-Paul Behr; Barbara A Demeneix
Journal:  J Gene Med       Date:  2005-02       Impact factor: 4.565

10.  Functional polarity is introduced by Dicer processing of short substrate RNAs.

Authors:  Scott D Rose; Dong-Ho Kim; Mohammed Amarzguioui; Jeremy D Heidel; Michael A Collingwood; Mark E Davis; John J Rossi; Mark A Behlke
Journal:  Nucleic Acids Res       Date:  2005-07-26       Impact factor: 16.971

View more
  121 in total

1.  A cell-penetrating helical polymer for siRNA delivery to mammalian cells.

Authors:  Nathan P Gabrielson; Hua Lu; Lichen Yin; Kyung Hoon Kim; Jianjun Cheng
Journal:  Mol Ther       Date:  2012-05-29       Impact factor: 11.454

2.  Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing.

Authors:  Minseon Cho; Yi Xiao; Jeff Nie; Ron Stewart; Andrew T Csordas; Seung Soo Oh; James A Thomson; H Tom Soh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-12       Impact factor: 11.205

Review 3.  Cell-specific aptamer-mediated targeted drug delivery.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Oligonucleotides       Date:  2010-12-23

4.  Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Authors:  Jiehua Zhou; C Preston Neff; Xiaoxuan Liu; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; Tawfik Aboellail; Yuanyu Huang; Quan Du; Zicai Liang; Ling Peng; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 5.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

Review 6.  Nucleic acid aptamers: clinical applications and promising new horizons.

Authors:  X Ni; M Castanares; A Mukherjee; S E Lupold
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 7.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

8.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.

Authors:  William M Rockey; Frank J Hernandez; Sheng-You Huang; Song Cao; Craig A Howell; Gregory S Thomas; Xiu Ying Liu; Natalia Lapteva; David M Spencer; James O McNamara; Xiaoqin Zou; Shi-Jie Chen; Paloma H Giangrande
Journal:  Nucleic Acid Ther       Date:  2011-10       Impact factor: 5.486

9.  Silencing prostate cancer.

Authors:  Ivanka Toudjarska; Antonin de Fougerolles
Journal:  Nat Biotechnol       Date:  2009-09       Impact factor: 54.908

Review 10.  Targeted delivery systems for oligonucleotide therapeutics.

Authors:  Bo Yu; Xiaobin Zhao; L James Lee; Robert J Lee
Journal:  AAPS J       Date:  2009-03-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.